bioRxivImmunology
PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques
K. D. Kauffman, S. Sakai, N. E. Lora, S. Namasivayam, P. J. Baker, O. Kamenyeva, T. W. Foreman, C. E. Nelson, D. Oliveira-de-Souza, C. L. Vinhaes, Z. Yaniv, C. S. Lindestam Arleham, A. Sette, G. J. Freeman, R. Moore, the NIAID/DIR Tuberculosis Imaging Program, A. Sher, K. D. Mayer-Barber, B. B. Andrade, J. Kabat, L. E. Via, D. L. Barber
Abstract
Boosting immune cell function by targeting the co-inhibitory receptor PD-1 may have applications in the treatment of chronic infections. Here we examine the role of PD-1 during Mycobacterium tuberculosis (Mtb) infection of rhesus macaques. Animals treated with PD-1 mAb developed worse disease and higher granuloma bacterial loads compared to isotype control treated monkeys. PD-1 blockade increased the number and functionality of granuloma Mtb-specific CD8 T cells. In contrast, Mtb-specific CD4 T cells in PD-1 treated macaques were not increased in number or function in granulomas, upregulated high levels of CTLA-4 and exhibited reduced intralesional trafficking in live imaging studies. In granulomas of PD-1 treated animals, multiple pro-inflammatory cytokines were elevated, and more cytokines correlated with bacterial loads, leading to the identification of a role for caspase 1 in the exacerbation of tuberculosis after PD-1 blockade. Lastly, increased Mtb bacterial loads after PD-1 blockade were found to associate with the composition of the intestinal microbiota prior to infection in individual macaques. Therefore, PD-1-mediated co-inhibition is required for control of Mtb infection in macaques, perhaps due to its role in dampening detrimental inflammation as well as allowing for normal CD4 T cell responses.
- organism: rat
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Early cellular mechanism of type I interferon-driven susceptibility to tuberculosis
D. I. Kotov, O. V. Lee, … R. E. Vance·bioRxiv·Oct 6, 2022
- c-Myc inhibits macrophage antimycobacterial response in Mycobacterium tuberculosis infection
Edoardo Sarti, Cédric Dollé, … Johannes Nemeth·The Journal of Infectious DiseasesPeer-reviewed·Aug 26, 2025
- Protein Kinase C δ: a critical hub regulating macrophage immunomodulatory functions during Mycobacterium tuberculosis infection
Rudranil Hazra, Mumin Ozturk, … Suraj P. Parihar·bioRxiv·May 19, 2025
- Mast cells promote pathology and susceptibility in tuberculosis
Ananya Gupta, Vibha Taneja, … Shabaana A. Khader·eLifePeer-reviewed·Jan 28, 2026
- The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas
T. Cleverley, S. Peddineni, … D. Kalman·bioRxiv·Nov 28, 2022
- Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions
Erin McCaffrey, Alea C. Delmastro, … Smriti Mehra·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 11, 2026